Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata

Table 1

Demographic characteristics of patients.

Patient number	Age	Gender	Duration of disease (months)	Other autoimmune disease	Side effects	AA subtype	Tofacitinib dosage	Duration of therapy, mo	Nail involvement
1	14	Male	12	—	—	AU	10 mg/daily for 12 months, then 5 mg/daily for 28 months	36	—
2	17	Male	84	—	—	AU	10 mg/daily	6	+
3	17	Male	156	—	—	AU	10 mg/daily	12	+
4	15	Male	60	—	Upper respiratory tract infection	AU	10 mg/daily	24	+
5	14	Female	36	—	—	AA	10 mg/daily	12	—
6	16	Female	60	—	—	AT	10 mg/daily	18	+
7	12	Male	36	—	—	AA	10 mg/daily	12	+
8	12	Male	108	Vitiligo	—	AT	10 mg/daily	12	—
9	14	Male	36	—	—	AU	10 mg/daily	6	—

AU: alopecia universalis, AA: alopecia areata, AT: alopecia totalis.